---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010802"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:28:46.568783+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus Q2 LOQTORZI rev $10M (+36% QoQ); UDENYCA divestiture closed for $483M

## Summary
- LOQTORZI net revenue $10.0M in Q2 2025, up 36% from $7.3M in Q1 2025 and $3.8M in Q2 2024.
- UDENYCA divestiture completed April 11, 2025; Coherus received $483.4M cash and is eligible for up to $75M milestones.
- Used proceeds to repay substantially all $230M of 2026 Convertible Notes and buy out royalty rights for $47.7M.
- Q2 2025 net loss from continuing ops $44.9M ($0.39 diluted loss) vs $54.9M ($0.48) YoY; non-GAAP net loss $39.0M.
- Cash, cash equivalents and marketable securities $238M at June 30, 2025; CHS-114 and casdozokitug data readouts expected 1H 2026.

## SEC filing metadata
- accession: 0001558370-25-010802
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/0001558370-25-010802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010802
- JSON: https://secwatch.observer/filing/0001558370-25-010802.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.